RxDoctor Payments DataLook up a doctor →

Bassil Aish, MD

Family Medicine · Huntington Beach, CANPI 1124015888

Payments from drug & device makers

$2,643,408in general payments, 2019–2025

Across 596 payments — averaging $4435.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1.7M
  • Endo Pharmaceuticals Inc.$507K
  • Teva Pharmaceuticals USA, Inc.$246K
  • Astrazeneca UK Limited$87K
  • GSK$68K
  • Galderma Laboratories, L.p.$34K
  • plus $24K from 43 others

What the payments were for

  • Travel & lodging$1381%
  • Food & beverage$9,31499%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,643,408 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$388,483
Medicare patients
229
Services billed
3,460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban63$43,475
FarxigaDapagliflozin Propanediol59$42,068
OzempicSemaglutide30$32,171
JanuviaSitagliptin Phosphate24$26,884
JardianceEmpagliflozin28$18,341
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$6,792
LinzessLinaclotide11$6,002
Spiriva HandihalerTiotropium Bromide12$5,637
Arnuity ElliptaFluticasone Furoate11$4,811
Dexlansoprazole DrDexlansoprazole21$3,910
Clobetasol Propionate12$3,640
Fluticasone-VilanterolFluticasone/Vilanterol11$3,582
Tadalafil16$3,235
EdarbiAzilsartan Medoxomil13$3,081
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine14$3,005

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$261$45,77475 claims
AstraZenecaFarxiga$1,678,367$42,06859 claims
Novo NordiskOzempic$157$32,17130 claims
MerckJanuvia$158$26,88424 claims
Boehringer IngelheimJardiance$49$18,34128 claims
GSKTrelegy Ellipta, Arnuity Ellipta$67,776$11,60323 claims
AbbVieLinzess, Synthroid$937$7,40834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Huntington Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →